| Scrip Code | 543828 |
|---|---|
| NSE Symbol | SUDARSHAN |
| MSEI Symbol | NOTLISTED |
| ISIN | INE00TV01023 |
| Name of company | SUDARSHAN PHARMA INDUSTRIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 29-10-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 26-10-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Second quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Chemicals and Solvents |
| Start date and time of board meeting | 29-10-2026 19:00:00 |
| End date and time of board meeting | 29-10-2026 22:00:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 30-04-2026 |
| Indicate Company website link for updated RPT policy of the Company | https://www.sudarshanpharma.com/wp-content/uploads/2026/05/RPT_Policy_Revised.pdf |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| NOT APPLICABLE | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-09-2026 | 30-09-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 20,501.80 | 37,067.83 | |
| Other income | 184.37 | 319.75 | |
| Total income | 20,686.17 | 37,387.58 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 157.58 | 264.83 |
| (b) | Purchases of stock-in-trade | 19,175.07 | 35,054.87 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (2,104.29) | (3,972.44) |
| (d) | Employee benefit expense | 178.85 | 351.74 |
| (e) | Finance costs | 1,034.62 | 1,854.08 |
| (f) | Depreciation, depletion and amortisation expense | 126.46 | 255.58 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 1,024.53 | 1,671.82 |
| Total other expenses | 1,024.53 | 1,671.82 | |
| Total expenses | 19,592.82 | 35,480.48 | |
| 3 | Total profit before exceptional items and tax | 1,093.35 | 1,907.10 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 1,093.35 | 1,907.10 |
| 6 | Tax expense | ||
| 7 | Current tax | 360.22 | 578.17 |
| 8 | Deferred tax | (46.38) | (54.76) |
| 9 | Total tax expenses | 313.84 | 523.41 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 779.51 | 1,383.69 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 779.51 | 1,383.69 |
| 17 | Other comprehensive income net of taxes | 0.38 | 0.76 |
| 18 | Total Comprehensive Income for the period | 779.89 | 1,384.45 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,544.71 | 2,544.71 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.32 | 0.56 | |
| Diluted earnings (loss) per share from continuing operations | 0.32 | 0.56 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.32 | 0.56 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.32 | 0.56 | |
| 24 | Debt equity ratio | 2.0300 | 2.0300 |
| 25 | Debt service coverage ratio | 1.6800 | 1.6600 |
| 26 | Interest service coverage ratio | 2.0600 | 2.0300 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes to Standalone Financial results: 1. The Financial Statements has been reviewed and recommended by Members of the Audit Committee and approved by the Board of Directors at their respective meetings held on October 29, 2026. The statutory auditors have issued an unmodified report on these results. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and rules amended from time to time. 2. The Company is engaged in manufacturing of API, Jobwork manufacturing in Pharmaceuticals items and traders in chemicals and solvents in India. The Company is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment and the segment-wise disclosure requirement of lND AS 108 on operating segment is not applicable to it. 3. The previous periods’ figures have been re-grouped / re-arranged / re-casted wherever necessary to make it comparable with the current period. 4. The Statutory Auditors have conducted a limited review of the above mentioned quarterly results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Report of the statutory auditors will be uploaded on the websites of BSE Limited and National Stock Exchange of India Limited along-with the results and is also available on the Company's website www.sudarshanpharma.com. 5. W.e.f. 27th October 2026, the Company successfully completed the migration of its equity shares from the SME Platform of BSE Limited to the Main Board of BSE Limited and listing on the main board of National Stock Exchange of India Limited, in accordance with the applicable provisions of the Securities and Exchange Board of India (SEBI) regulations and the relevant rules, circulars and guidelines. 6. During Quarterly and Half year ended 30th September 2026, the Company decided to discontinue its manufacturing operations at the Palghar unit. The decision was taken after evaluating the unit's operating performance and its contribution to the Company's financial results. The closure is expected to help the Company rationalize fixed and operating costs, minimize further losses, and enable management to focus its resources on more sustainable and profitable operations. 7. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (i) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Nine Crores Eighteen Lakhs Eighty-Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made. Till 30th September, 2026, the Company had received an amount of Rs.7,48,81,069/- (including interest) out of the total outstanding amount and the balance would be received by the Company in future. 8. The Board of Directors of the Company accorded its consent to raise funds up to Rs.1,500 Crores (Rupees Fifteen Hundred Crores) by issuing Foreign Currency Convertible Bonds (FCCBs) and other securities. At the Board Meeting held on 15th May 2026, the Directors accorded its approval to issue of upto U.S. $ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches. At the Board Meeting held on 21st May 2026, the Directors accorded its approval to issue and allot U.S.$10,000,000 aggregate value of FCCBs to the subscribers, with an option with the Company to procure subscribers for up to an additional U.S.$10,000,000 of Bonds on the same terms within 60 days from the Issue Date and approved and confirmed the allotment of 10,000 8% senior unsecured foreign currency convertible bonds due 2029 of face value of USD 1,000 each, convertible into fully paid-up equity shares of face value of Re.1 each of the Company at a price of Rs.30.19/-. The proceeds of the aforesaid allotment were received in tranches on 27th May 2026 and 4th June 2026 comprising of USD 900,000 and USD 100,000 respectively. The above FCCBs are accounted in accordance with Ind AS 32 on Financial Instruments: Presentation and Ind AS 109 - Financial Instruments. At the FCCB Committee Meeting held on 19th August 2026, approved the allotment of 48,11,730 (Forty Eight Lakhs Eleven Thousand Seven Hundred And Thirty) fully paid-up equity shares of face value Rs.1/- each upon conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15,00,000. The equity shares were been allotted at an issue price of Rs.30.19 per share, comprising a premium of Rs. 29.19 per share. Following the aforesaid allotment, the total issued equity shares of the Company stand at 25,44,70,600, aggregating to an issued equity share capital of Rs. 25,44,70,600/- 9. The Warrants Committee of the Company at its Meeting held on 12th June 2026 accorded it’s approval to allot 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.98 each (including a premium of Rs.15.98 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each on 18th December 2024, to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters, on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,20,000/- per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares. Consequently, the issued and paid-up capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re. 1/- each. 10. As at September 30th, 2026 and June 30th, 2026, there are potential dilutive equity share in the nature of FCCB. The potential dilutive equity shares has an anti-dilutive effect. Hence no dilution effect has been considered for the quarter ended September 30, 2026 and June 30, 2026. 11. On 28th September 2026, the Company completed sale of 2,09,100 equity shares of Rs.10/- each (51.00% of the total paid-up capital of Ishwari) held by the Company in Ishwari Healthcare Private Limited, subsidiary company at a consideration of Rs.1.40 Crores. Consequent to the aforesaid sale, the shareholding of the Company in Ishwari has been reduced from 51.00% to Nil and Ishwari has ceased to be a subsidiary of the Company. 12. The Company has incorporated the following subsidiary company during the period ended 30th September 2026: W. e. f. 5t June, 2026, “Sudarshan Industries Inc.” (hereinafter referred to as “Sudarshan USA”) was incorporated as a wholly-owned subsidiary of the Company. The Company has subscribed to 1,00,00,000 shares of USD0.00001 each of Sudarshan USA (approx. Rs.9,600/-) (100.00% of the paid-up share capital). The main object of Sudarshan USA is to carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical Ingredients, antibiotics, drugs, medicines, biologicals, neutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2026 | |
| Date of end of reporting period | 30-09-2026 | |
| Whether results are audited or unaudited | Unaudited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 7,175.86 | |
| Capital work-in-progress | 794.57 | |
| Investment property | 1,131.10 | |
| Goodwill | 0.00 | |
| Other intangible assets | 949.61 | |
| Intangible assets under development | 0.00 | |
| Biological assets other than bearer plants | 0.00 | |
| Investments accounted for using equity method | 0.00 | |
| Non-current financial assets | ||
| Non-current investments | 625.50 | |
| Trade receivables, non-current | 0.00 | |
| Loans, non-current | 0.00 | |
| Other non-current financial assets | ||
| 1 | Other non-current financial assets | 5,735.37 |
| Total of other non-current financial assets | 5,735.37 | |
| Total non-current financial assets | 6,360.87 | |
| Deferred tax assets (net) | 73.89 | |
| Other non-current assets | ||
| 1 | Other non-current assets | 608.56 |
| Total of other non-current assets | 608.56 | |
| Total non-current assets | 17,094.46 | |
| 2 | Current assets | |
| Inventories | 24,697.21 | |
| Current financial asset | ||
| Current investments | 0.00 | |
| Trade receivables, current | 22,679.16 | |
| Cash and cash equivalents | 64.92 | |
| Bank balance other than cash and cash equivalents | 0.00 | |
| Loans, current | 344.06 | |
| Other current financial assets | ||
| Total of other current financial assets | 5,449.90 | |
| Total current financial assets | 28,538.04 | |
| Current tax assets (net) | 0.00 | |
| Other current assets | ||
| 1 | Other current assets | 2,687.81 |
| Total of other current assets | 2,687.81 | |
| Total current assets | 55,923.06 | |
| 3 | Non-current assets classified as held for sale | 0.00 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 |
| Total assets | 73,017.52 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 2,544.71 | |
| Other equity | 16,751.71 | |
| Total equity attributable to owners of parent | 19,296.42 | |
| Non controlling interest | ||
| Total equity | 19,296.42 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 14,638.57 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | |
| Total Trade payable | 0.00 | |
| Other non-current financial liabilities | ||
| 1 | Other non-current financial liabilities | 33.27 |
| 2 | Lease liabilities | 99.74 |
| Total of other non-current financial liabilities | 133.01 | |
| Total non-current financial liabilities | 14,771.58 | |
| Provisions, non-current | 20.86 | |
| Deferred tax liabilities (net) | 0.00 | |
| Deferred government grants, Non-current | 0.00 | |
| Other non-current liabilities | ||
| Total of other non-current liabilities | ||
| Total non-current liabilities | 14,792.44 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 24,604.60 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 5,947.24 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 6,990.88 | |
| Total Trade payable | 12,938.12 | |
| Other current financial liabilities | ||
| 1 | Other current financial liabilities | 19.09 |
| 2 | Lease Liabilities | 57.27 |
| Total of other current financial liabilities | 76.36 | |
| Total current financial liabilities | 37,619.08 | |
| Other current liabilities | 76.91 | |
| 1 | Other current liabilities | 76.91 |
| Total of other current liabilities | 76.91 | |
| Provisions, current | 1.74 | |
| Current tax liabilities (Net) | 1,230.93 | |
| Deferred government grants, Current | 0.00 | |
| Total current liabilities | 38,928.66 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0.00 |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 |
| Total liabilities | 53,721.10 | |
| Total equity and liabilites | 73,017.52 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-07-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-09-2026 | 30-09-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-09-2026 | 30-09-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement (loss)/gain on defined benefit plan Grauity and Leave | 0.51 | 1.02 |
| Total Amount of items that will not be reclassified to profit and loss | 0.51 | 1.02 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.13 | 0.26 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 0.38 | 0.76 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | ||||
| B | Date of end of reporting period | 30-09-2026 | ||||
| C | Whether results are audited or unaudited | Unaudited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 1,907.10 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 1,854.08 | |||||
| Adjustments for decrease (increase) in inventories | (4,031.69) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (2,965.99) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (53.59) | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 140.49 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | (1,885.89) | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | (373.61) | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 255.58 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 1.19 | |||||
| Adjustments for provisions, non-current | 2.02 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 229.87 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 156.64 | |||||
| Adjustments for share-based payments | 0.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 0.00 | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | 260.04 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (6,724.14) | |||||
| Net cash flows from (used in) operations | (4,817.04) | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 79.39 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | (4,896.43) | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 4,700.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 2,343.22 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 169.00 | |||||
| Purchase of property, plant and equipment | 0.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 36.89 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) investing activities | (6,837.33) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 1,146.35 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 12,634.01 | |||||
| Repayments of borrowings | 411.54 | |||||
| Payments of lease liabilities | 47.93 | |||||
| Dividends paid | 0.00 | |||||
| Interest paid | 1,533.11 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | 11,787.78 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 54.02 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | 54.02 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 10.90 | |||||
| Cash and cash equivalents cash flow statement at end of period | 64.92 | |||||
| Whether results are audited or unaudited | Unaudited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | NGST & Associates | Yes | 31-08-2027 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | SUDARSHAN PHARMA INDUSTRIES LIMITED | HEMAL MEHTA | MANAGING DIRECTOR | Remuneration | 120.00 | approved | 48.00 | 0.00 | 0.00 | ||||||||||||||||
| 2 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN MEHTA | MANAGING DIRECTOR | Remuneration | 120.00 | approved | 48.00 | 0.00 | 0.00 | ||||||||||||||||
| 3 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RUSHABH PATIL | INDEPENDENT DIRECTOR | Any other transaction | DIRECTOR SITTING FEES | 2.00 | approved | 0.88 | 0.29 | 0.29 | |||||||||||||||
| 4 | SUDARSHAN PHARMA INDUSTRIES LIMITED | DR VINAY KUMAR PANDEY | NON-EXECUTIVE DIRECTOR | Any other transaction | DIRECTOR SITTING FEES | 2.00 | approved | 0.24 | 0.00 | 0.00 | |||||||||||||||
| 5 | SUDARSHAN PHARMA INDUSTRIES LIMITED | JAYA SHARMA | INDEPENDENT DIRECTOR | Any other transaction | DIRECTOR SITTING FEES | 2.00 | approved | 0.40 | 0.34 | 0.12 | |||||||||||||||
| 6 | SUDARSHAN PHARMA INDUSTRIES LIMITED | HEMAL MEHTA | MANAGING DIRECTOR | Any other transaction | LOAN TAKEN | 500.00 | approved | 401.50 | 0.00 | 0.00 | |||||||||||||||
| 7 | SUDARSHAN PHARMA INDUSTRIES LIMITED | HEMAL MEHTA | MANAGING DIRECTOR | Any other transaction | LOAN REPAID | 500.00 | approved | 401.50 | 0.00 | 0.00 | |||||||||||||||
| 8 | SUDARSHAN PHARMA INDUSTRIES LIMITED | HEMAL MEHTA | MANAGING DIRECTOR | Any other transaction | RENT EXPENSE | 100.00 | approved | 5.78 | 0.00 | 0.00 | |||||||||||||||
| 9 | SUDARSHAN PHARMA INDUSTRIES LIMITED | ISHWARI HEALTHCARE PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN GIVEN | 1,500.00 | approved | 186.96 | 162.03 | 268.79 | Inter-corporate deposit | 12.00 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 10 | SUDARSHAN PHARMA INDUSTRIES LIMITED | ISHWARI HEALTHCARE PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN GIVEN RECEIVED BACK | 1,500.00 | approved | 80.20 | 0.00 | 0.00 | |||||||||||||||
| 11 | SUDARSHAN PHARMA INDUSTRIES LIMITED | ISHWARI HEALTHCARE PRIVATE LIMITED | SUBSIDIARY COMPANY | Interest received | 200.00 | approved | 16.48 | 19.61 | 34.44 | ||||||||||||||||
| 12 | SUDARSHAN PHARMA INDUSTRIES LIMITED | ISHWARI HEALTHCARE PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | RENT INCOME | 100.00 | approved | 24.00 | 115.28 | 146.28 | |||||||||||||||
| 13 | SUDARSHAN PHARMA INDUSTRIES LIMITED | LIFE SCIENCE CHEMICAL PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN TAKEN | 250.00 | approved | 0.00 | 249.59 | 236.57 | Inter-corporate deposit | 9.00 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 14 | SUDARSHAN PHARMA INDUSTRIES LIMITED | LIFE SCIENCE CHEMICAL PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN REPAID | 250.00 | approved | 13.02 | 0.00 | 0.00 | |||||||||||||||
| 15 | SUDARSHAN PHARMA INDUSTRIES LIMITED | LIFE SCIENCE CHEMICAL PRIVATE LIMITED | SUBSIDIARY COMPANY | Interest paid | 50.00 | approved | 12.05 | 20.73 | 31.58 | ||||||||||||||||
| 16 | SUDARSHAN PHARMA INDUSTRIES LIMITED | MAGICREMEDI PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A SPOUSE OF DIRECTOR IS A DIRECTOR | Any other transaction | LOAN TAKEN | 1,500.00 | approved | 113.00 | 184.00 | 0.00 | Inter-corporate deposit | 9.00 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 17 | SUDARSHAN PHARMA INDUSTRIES LIMITED | MAGICREMEDI PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A SPOUSE OF DIRECTOR IS A DIRECTOR | Any other transaction | LOAN REPAID | 1,500.00 | approved | 306.13 | 0.00 | 0.00 | |||||||||||||||
| 18 | SUDARSHAN PHARMA INDUSTRIES LIMITED | MAGICREMEDI PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A SPOUSE OF DIRECTOR IS A DIRECTOR | Interest paid | 300.00 | approved | 9.78 | 0.33 | 0.00 | ||||||||||||||||
| 19 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RADHE | A PROPRIETORSHIP FIRM IN WHICH A DIRECTOR IS A SOLE PROPRIETOR | Any other transaction | RENT EXPENSE | 100.00 | approved | 8.09 | 0.00 | 0.00 | |||||||||||||||
| 20 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RATNA LIFESCIENCES PRIVATE LIMITED | SUBSIDIARY COMPANY | Sale of goods or services | 1,500.00 | approved | 242.04 | 0.00 | 0.00 | ||||||||||||||||
| 21 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RATNA LIFESCIENCES PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN GIVEN | 1,500.00 | approved | 431.97 | 68.42 | 32.00 | Inter-corporate deposit | 9.00 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 22 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RATNA LIFESCIENCES PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN GIVEN RECEIVED BACK | 1,500.00 | approved | 468.39 | 0.00 | 0.00 | |||||||||||||||
| 23 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RATNA LIFESCIENCES PRIVATE LIMITED | SUBSIDIARY COMPANY | Interest received | 200.00 | approved | 9.69 | 20.19 | 29.88 | ||||||||||||||||
| 24 | SUDARSHAN PHARMA INDUSTRIES LIMITED | RATNA LIFESCIENCES PRIVATE LIMITED | SUBSIDIARY COMPANY | Purchase of goods or services | 1,500.00 | approved | 133.39 | 0.00 | 0.00 | ||||||||||||||||
| 25 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMICALS | A PROPRIETORSHIP FIRM IN WHICH A DIRECTOR IS A SOLE PROPRIETOR | Sale of goods or services | 2,000.00 | approved | 15.80 | 0.00 | 0.00 | ||||||||||||||||
| 26 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMICALS | A PROPRIETORSHIP FIRM IN WHICH A DIRECTOR IS A SOLE PROPRIETOR | Any other transaction | Other Income | 50.00 | approved | 4.59 | 0.00 | 0.00 | |||||||||||||||
| 27 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMICALS | A PROPRIETORSHIP FIRM IN WHICH A DIRECTOR IS A SOLE PROPRIETOR | Purchase of goods or services | 2,000.00 | approved | 40.80 | 0.00 | 457.06 | ||||||||||||||||
| 28 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMSOLVE INDUSTRY PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | OTHER INCOME | 50.00 | approved | 1.49 | 0.00 | 0.00 | |||||||||||||||
| 29 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMSOLVE INDUSTRY PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | LOAN TAKEN | 1,500.00 | approved | 1,202.04 | 0.00 | 119.36 | Inter-corporate deposit | 9.00 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 30 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMSOLVE INDUSTRY PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | LOAN REPAID | 1,500.00 | approved | 1,083.08 | 0.00 | 0.00 | |||||||||||||||
| 31 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SACHIN CHEMSOLVE INDUSTRY PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Interest paid | 300.00 | approved | 7.29 | 0.58 | 6.56 | ||||||||||||||||
| 32 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN CHEMPHARMA INDIA PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | RENT EXPENSE | 50.00 | approved | 13.18 | 0.00 | 0.00 | |||||||||||||||
| 33 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN CHEMPHARMA INDIA PRIVATE LIMITED | A PRIVATE COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | OTHER INCOME | 50.00 | approved | 0.75 | 0.00 | 0.00 | |||||||||||||||
| 34 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN PHARMA LIFESCIENCE PRIVATE LIMITED | SUBSIDIARY COMPANY | Any other transaction | LOAN GIVEN | 250.00 | approved | 1.00 | 0.00 | 1.00 | Inter-corporate deposit | 0 | Repayable on demand | Unsecured | General Corporate Purpose | ||||||||||
| 35 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN SOLVENTS INDUSTRIES LIMITED | A PUBLIC COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | LOAN REPAID | 1,500.00 | approved | 662.25 | 662.25 | 0.00 | |||||||||||||||
| 36 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN SOLVENTS INDUSTRIES LIMITED | A PUBLIC COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Purchase of goods or services | 1,500.00 | approved | 10.86 | 0.00 | 0.00 | ||||||||||||||||
| 37 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SUDARSHAN SOLVENTS INDUSTRIES LIMITED | A PUBLIC COMPANY IN WHICH A DIRECTOR IS A DIRECTOR | Any other transaction | OTHER INCOME | 50.00 | approved | 2.11 | 0.00 | 0.00 | |||||||||||||||
| 38 | SUDARSHAN PHARMA INDUSTRIES LIMITED | UPSTREAM REFINERY SOLUTION LLP | A LIMITED LIALBILITY PARTNERSHIP FIRM IN WHICH A DIRECTOR IS A DESIGNATED PARTNER | Sale of goods or services | 1,500.00 | approved | 167.25 | 26.59 | 105.01 | ||||||||||||||||
| 39 | SUDARSHAN PHARMA INDUSTRIES LIMITED | DEVANGI MEHTA | SPOUSE OF DIRECTOR | Any other transaction | SALARY PAID | 12.00 | approved | 5.40 | 0.00 | 0.00 | |||||||||||||||
| 40 | SUDARSHAN PHARMA INDUSTRIES LIMITED | NAMRATA MEHTA | SPOUSE OF DIRECTOR | Any other transaction | SALARY PAID | 12.00 | approved | 5.40 | 0.00 | 0.00 | |||||||||||||||
| 41 | SUDARSHAN PHARMA INDUSTRIES LIMITED | VASANTRAI MEHTA | FATHER OF DIRECTOR | Any other transaction | SALARY PAID | 12.00 | approved | 5.70 | 0.00 | 0.00 | |||||||||||||||
| 42 | SUDARSHAN PHARMA INDUSTRIES LIMITED | JATIN MEHTA | BROTHER OF DIRECTOR | Any other transaction | SALARY PAID | 12.00 | approved | 5.70 | 0.00 | 0.00 | |||||||||||||||
| 43 | SUDARSHAN PHARMA INDUSTRIES LIMITED | DARSHNA MEHTA | SISTER IN LAW OF DIRECTOR | Any other transaction | SALARY PAID | 12.00 | approved | 5.40 | 0.00 | 0.00 | |||||||||||||||
| 44 | SUDARSHAN PHARMA INDUSTRIES LIMITED | NIRAV SHAH | COMPANY SECRETARY OF THE COMPANY | Any other transaction | SALARY PAID | 10.00 | approved | 4.85 | 0.00 | 0.00 | |||||||||||||||
| 45 | SUDARSHAN PHARMA INDUSTRIES LIMITED | SHARAD KATHAWATE | CFO OF THE COMPANY | Any other transaction | SALARY PAID | 24.00 | approved | 11.61 | 0.00 | 0.00 | |||||||||||||||
| Total value of transaction during the reporting period | 6,218.04 | ||||||||||||||||||||||||